VEA
MRNA icon

Virtus ETF Advisers’s Moderna MRNA Stock Holding History

Virtus ETF Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-8,166
Closed -$340K – 649
2024
Q4 		$340K Buy
8,166
+5,898
+260% +$282K 0.14% 218
2024
Q3 		$152K Hold
2,268
– – 0.07% 324
2024
Q2 		$269K Sell
2,268
-2,169
-49% -$274K 0.13% 241
2024
Q1 		$473K Buy
4,437
+638
+17% +$64.3K 0.25% 182
2023
Q4 		$378K Buy
3,799
+1,385
+57% +$116K 0.24% 175
2023
Q3 		$249K Sell
2,414
-5,795
-71% -$646K 0.15% 226
2023
Q2 		$997K Buy
8,209
+6,737
+458% +$899K 0.59% 12
2023
Q1 		$226K Buy
1,472
+24
+2% +$3.96K 0.12% 298
2022
Q4 		$260K Sell
1,448
-492
-25% -$80.4K 0.14% 301
2022
Q3 		$229K Sell
1,940
-5,173
-73% -$785K 0.09% 304
2022
Q2 		$1.02M Buy
7,113
+5,771
+430% +$825K 0.38% 87
2022
Q1 		$231K Hold
1,342
– – 0.1% 188
2021
Q4 		$341K Sell
1,342
-866
-39% -$253K 0.13% 184
2021
Q3 		$850K Sell
2,208
-199
-8% -$73.4K 0.37% 95
2021
Q2 		$566K Sell
2,407
-1,624
-40% -$290K 0.23% 120
2021
Q1 		$528K Buy
4,031
+106
+3% +$15.4K 0.22% 141
2020
Q4 		$410K Sell
3,925
-1,049
-21% -$106K 0.17% 152
2020
Q3 		$352K Sell
4,974
-686
-12% -$47.8K 0.18% 187
2020
Q2 		$363K Sell
5,660
-13,644
-71% -$747K 0.17% 249
2020
Q1 		$578K Sell
19,304
-2,829
-13% -$65.1K 0.24% 157
2019
Q4 		$433K Buy
22,133
+5,736
+35% +$102K 0.07% 231
2019
Q3 		$261K Sell
16,397
-914
-5% -$13.5K 0.05% 212
2019
Q2 		$253K Buy
+17,311
New +$372K 0.05% 273

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Virtus ETF Advisers's MRNA Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Moderna (MRNA) in Q1 2025, closing a stake of 8,166 shares — an estimated $340K sold.

Virtus ETF Advisers first reported a position in MRNA in Q2 2019 and held it in 23 quarters. The position peaked at $1.02M in Q2 2022. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 8,166 Moderna shares in Q1 2025, an estimated $340K.
  • Virtus ETF Advisers first reported a position in Moderna in Q2 2019 and held it in 23 quarters.
  • Virtus ETF Advisers's Moderna position peaked at $1.02M in Q2 2022.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.